NanoString Technologies (NSTGQ) Competitors $0.07 0.00 (0.00%) (As of 10/16/2024) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsOptions ChainSEC FilingsTrends NSTGQ vs. PMCB, TSBX, SNTI, NKGN, EVAX, COEP, APTO, BCLI, ONVO, and KLTOShould you be buying NanoString Technologies stock or one of its competitors? The main competitors of NanoString Technologies include PharmaCyte Biotech (PMCB), Turnstone Biologics (TSBX), Senti Biosciences (SNTI), NKGen Biotech (NKGN), Evaxion Biotech A/S (EVAX), Coeptis Therapeutics (COEP), Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), and Klotho Neurosciences (KLTO). These companies are all part of the "biological products, except diagnostic" industry. NanoString Technologies vs. PharmaCyte Biotech Turnstone Biologics Senti Biosciences NKGen Biotech Evaxion Biotech A/S Coeptis Therapeutics Aptose Biosciences Brainstorm Cell Therapeutics Organovo Klotho Neurosciences PharmaCyte Biotech (NASDAQ:PMCB) and NanoString Technologies (NASDAQ:NSTGQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Is PMCB or NSTGQ more profitable? PharmaCyte Biotech has a net margin of 0.00% compared to NanoString Technologies' net margin of -102.44%. PharmaCyte Biotech's return on equity of 1.38% beat NanoString Technologies' return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 1.38% 0.71% NanoString Technologies -102.44%N/A -53.79% Which has more risk & volatility, PMCB or NSTGQ? PharmaCyte Biotech has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Does the MarketBeat Community prefer PMCB or NSTGQ? PharmaCyte Biotech and NanoString Technologies both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/ANanoString TechnologiesN/AN/A Which has higher valuation and earnings, PMCB or NSTGQ? PharmaCyte Biotech has higher earnings, but lower revenue than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.662.67NanoString Technologies$127.26M0.03-$159.54M-$3.53-0.02 Does the media favor PMCB or NSTGQ? In the previous week, PharmaCyte Biotech had 2 more articles in the media than NanoString Technologies. MarketBeat recorded 2 mentions for PharmaCyte Biotech and 0 mentions for NanoString Technologies. PharmaCyte Biotech's average media sentiment score of 0.44 beat NanoString Technologies' score of 0.00 indicating that PharmaCyte Biotech is being referred to more favorably in the media. Company Overall Sentiment PharmaCyte Biotech Neutral NanoString Technologies Neutral Do institutionals and insiders have more ownership in PMCB or NSTGQ? 34.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 76.8% of NanoString Technologies shares are owned by institutional investors. 1.0% of PharmaCyte Biotech shares are owned by company insiders. Comparatively, 3.1% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryPharmaCyte Biotech beats NanoString Technologies on 8 of the 12 factors compared between the two stocks. Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Get NanoString Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for NSTGQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NSTGQ vs. The Competition Export to ExcelMetricNanoString TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.45M$3.06B$5.35B$8.88BDividend YieldN/A1.76%4.98%4.04%P/E Ratio-0.0245.57132.0617.45Price / Sales0.03426.611,259.5098.78Price / CashN/A179.8139.0436.42Price / Book0.074.296.265.86Net Income-$159.54M-$42.42M$118.56M$224.86M7 Day PerformanceN/A-5.79%-2.16%-0.94%1 Month PerformanceN/A1.88%2.44%3.65%1 Year PerformanceN/A34.21%35.47%26.39% NanoString Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NSTGQNanoString TechnologiesN/A$0.07flatN/AN/A$3.45M$127.26M-0.02550PMCBPharmaCyte Biotech1.2022 of 5 stars$1.76-1.7%N/A-15.8%$13.52MN/A2.672Short Interest ↑TSBXTurnstone Biologics3.9233 of 5 stars$0.53-1.2%N/A-70.3%$12.21M$19.31M-0.1682Earnings ReportNews CoveragePositive NewsGap DownSNTISenti Biosciences0.834 of 5 stars$2.33+3.6%N/A-48.2%$10.67M$2.56M-0.184News CoveragePositive NewsGap DownNKGNNKGen BiotechN/A$0.28+12.2%N/A-91.2%$9.80M$80,000.00-0.05N/AGap UpEVAXEvaxion Biotech A/S3.4177 of 5 stars$1.76-0.3%N/A-74.4%$9.79M$70,000.00-6.0549Short Interest ↓News CoverageCOEPCoeptis Therapeutics0.7645 of 5 stars$0.21+6.7%N/A-82.2%$8.45M$80,000.00-0.442Short Interest ↑Gap UpAPTOAptose Biosciences2.8427 of 5 stars$0.39+1.3%N/A-85.9%$6.98MN/A-0.1331Analyst ForecastPositive NewsGap UpBCLIBrainstorm Cell Therapeutics4.4894 of 5 stars$1.13-3.4%N/A-57.8%$6.01MN/A-0.3340Analyst DowngradeShort Interest ↓News CoverageGap UpHigh Trading VolumeONVOOrganovo0.7064 of 5 stars$0.36+1.1%N/A-74.8%$5.59M$73,000.00-0.3420Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageKLTOKlotho NeurosciencesN/A$0.30-13.3%N/AN/A$5.17MN/A0.00N/AUpcoming EarningsPositive NewsGap Down Related Companies and Tools Related Companies PMCB Competitors TSBX Competitors SNTI Competitors NKGN Competitors EVAX Competitors COEP Competitors APTO Competitors BCLI Competitors ONVO Competitors KLTO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NSTGQ) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoString Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoString Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
